FDA approves landmark pancreatic cancer drug that’s shown to improve survival
Summary
The U.S. Food and Drug Administration (FDA) approved a new drug called daraxonrasib to treat the most common type of pancreatic cancer. This pill targets a mutated protein causing the cancer and nearly doubles patients' survival time compared to chemotherapy.Key Facts
- Daraxonrasib is the first drug to block a mutated protein found in over 90% of pancreatic cancers.
- It was approved by the FDA more than six months ahead of schedule.
- The drug nearly doubled median survival to 13.2 months compared to 6.7 months for chemotherapy.
- The treatment has fewer severe side effects than chemotherapy.
- The pancreatic cancer study involved 500 patients whose cancer had stopped responding to previous treatments.
- Pancreatic cancer is hard to detect early and has a low five-year survival rate of 13%.
- The drug uses a "molecular glue" to stick to KRAS mutations, which were previously considered untreatable.
- Revolution Medicines, based in California, is also testing this drug technology for other cancers like lung cancer.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
